新金融搜索:
首页 > 财经 > 财经热点

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Ran

发布时间:2020-01-12
Acquisition of worldwide exclusive rights adds extensive anti-IL-11 platform to Boehringer Ingelheim pipeline portfolio
Boehringer Ingelheim aims to develop therapies for multiple fibrotic human disorders, including non-alcoholic steatohepatitis (NASH) and interstitial lung diseases (ILDs)
Singapore-based Enleofen to receive in excess of one billion USD per product in upfront and success-based development and commercialization milestones

INGELHEIM AM RHEIN, Germany & SINGAPORE--()--Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced today the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer Ingelheim’s leading expertise and comprehensive pipeline in fibrotic diseases with Enleofen’s world-leading expertise in IL-11 biology and the company’s extensive range of therapeutic antibodies targeting this pathway.

“The impressive preclinical studies at Enleofen have revealed the potential of IL-11 blockade to treat a broad range of diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “We are excited to have these monoclonal antibodies in our pipeline and have the opportunity to accelerate their path to many patients whose needs are not met by current treatments.”

IL-11 is a cytokine, a protein certain cells of the body use to communicate, and plays a key role in fibro-inflammatory conditions. Blocking IL-11 action has been shown to inhibit disease across many organs (liver, lung, kidney, retina, bowel, heart and skin). In preclinical studies, antibody-based IL-11 antagonists were able to prevent and reverse inflammation and fibrosis, and restore organ function.

Enleofen is a spin out company from the National Heart Centre Singapore (NHCS) at SingHealth and Duke-NUS Medical School under the SingHealth Duke-NUS Academic Medical Centre (AMC), Singapore and exclusively licensed a suite of patents and number of antibody products when it was founded in 2017, from the AMC. Subsequent to this, Enleofen has built an extensive anti-IL-11 antibody platform and advanced its drug development programs towards the clinic. Boehringer Ingelheim will now develop this platform further and plans to work jointly with scientists at the AMC to accelerate the platform into clinical development. The initial focus will be on novel therapies for patients with NASH and ILDs, two of Boehringer Ingelheim’s core disease focus areas, with a potential to expand into further fibro-inflammatory conditions based on IL-11’s central role in disease.

“Enleofen is very excited to engage Boehringer Ingelheim, a leader in anti-fibrotic therapy R&D to develop further anti-IL-11 therapies to begin to address the unmet medical needs of patients worldwide,” said Prof Stuart Cook, Director and co-founder of Enleofen. “The preclinical data across a range of conditions are unprecedented and this new approach of targeting IL-11 could be a game changer”.

The acquisition of the IL-11 program from Enleofen strengthens Boehringer Ingelheim’s pipeline portfolio, which combines approaches that are effective across multiple fibrotic diseases with disease-specific approaches to achieve greater therapeutic effect and builds on the experience gained with nintedanib in fibrotic lung diseases. Boehringer Ingelheim will be solely responsible for the clinical, regulatory and commercial development of the licensed therapies. Under the terms of the agreement, Enleofen may receive earn out payments in excess of one billion USD per product in upfront and success-based development and commercialization milestones.

For references and notes to editors, please visit:

Contacts

Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672


Enleofen
Charu Srivastava

+65 91810614

Mariyam Haider

+65 86056752

来源:
作者:

>相关文章

最新文章
热点文章
  1. 1.Visa在全球范围内增加对女足的投入
  2. 2.所有2019年Gartner供应链大师和Gartn
  3. 3.IPValue子公司授权三星使用其收购的赛
  4. 4.MPEG LA推出电动汽车充电的一站式许可
  5. 5.Materion推出适合大电流应用的高导电
  6. 6.最新目的地扩增使AVOXI成为全球最大的
  7. 7.2019中国义乌进口商品博览会圆满落幕
  8. 8.联发科技获得IPValue Management的专
理财师推荐